Pulse Biosciences Q1 net loss narrows to $9.8M; $65M private placement with Executive Chairman

PULSE BIOSCIENCES, INC.

GAAP net loss of $9.8M vs $17.3M YoY; non-GAAP net loss of $8.6M vs $14.2M.
Cash and equivalents $54.1M as of March 31, 2023, up from $12.7M a year ago.
Entered $65M private placement with Executive Chairman Robert Duggan, canceling all indebtedness.
Appointed Dr. Gan Dunnington as Chief Medical Officer, Cardiac Surgery.
Completed FDA pre-submission for nsPFA surgical ablation clamp; advancing preclinical studies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PULSE BIOSCIENCES, INC. reported the fiscal quarter ended March 31, 2023 results: net income ($9.8) million.

Period: the fiscal quarter ended March 31, 2023
Net income: ($9.8) million
Result: reported results

Exact text from the filing

GAAP net loss for the three months ended March 31, 2023, was ($9.8) million compared to ($17.3) million for the three months ended March 31, 2022.

View on SEC.gov

Browse all earnings releases →

PULSE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-013949

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.